Choroid Plexus CarcinomaSymptoms, Doctors, Treatments, Advances & More
Learn About Choroid Plexus Carcinoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
CUIMC/Edward S. Harkness Eye Institute
Brian Marr is an Ophthalmologist practicing medicine in New York, New York. Dr. Marr is rated as a Distinguished provider by MediFind in the treatment of Choroid Plexus Carcinoma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Retinoblastoma, Melanoma of the Eye, Metastatic Uveal Melanoma, Uveal Melanoma, and Vitrectomy. Dr. Marr is board certified in Ophthalmology. Dr. Marr is currently accepting new patients.
David Malkin practices practicing medicine in Toronto, Canada. Mr. Malkin is rated as an Elite expert by MediFind in the treatment of Choroid Plexus Carcinoma. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Li-Fraumeni Syndrome, Choroid Plexus Carcinoma, Cerebral Ventricle Cancer, and Rhabdomyosarcoma.
Uri Tabori practices practicing medicine in Toronto, Canada. Mr. Tabori is rated as an Elite expert by MediFind in the treatment of Choroid Plexus Carcinoma. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Glioma, Gliomatosis Cerebri, Choroid Plexus Carcinoma, and Cerebral Ventricle Cancer.
Summary: The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) ne...
Summary: Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO cl...